Zobrazeno 1 - 10
of 138
pro vyhledávání: '"Joe B. Harford"'
Autor:
Manish Moghe, Sang-Soo Kim, Miaoyin Guan, Antonina Rait, Kathleen F. Pirollo, Joe B. Harford, Esther H. Chang
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7539 (2024)
Due to their inhibition of acetylcholinesterase, organophosphates are among the most toxic of chemicals. Pralidoxime (a.k.a 2-PAM) is the only acetylcholinesterase reactivator approved in the U.S., but 2-PAM only poorly traverses the blood–brain ba
Externí odkaz:
https://doaj.org/article/fa479bdacb484acfb87478c121a16f22
Autor:
Joe B. Harford
Publikováno v:
Viruses, Vol 15, Iss 12, p 2377 (2023)
As the world exits the global pandemic caused by the previously unknown SARS-CoV-2, we also mark the 30th anniversary of p53 being named “molecule of the year” by Science based on its role as a tumor suppressor. Although p53 was originally discov
Externí odkaz:
https://doaj.org/article/2604923f19be49dda12dc59ad45ab87d
Publikováno v:
Cells, Vol 11, Iss 21, p 3434 (2022)
Lung cancer is among the most common and lethal cancers and warrants novel therapeutic approaches to improving patient outcomes. Although immune checkpoint inhibitors (ICIs) have demonstrated substantial clinical benefits, most patients remain unresp
Externí odkaz:
https://doaj.org/article/f0521609cc37432ba671a44c0301d382
Autor:
Amanda L. Vogel, Jordan A. Freeman, Kalina Duncan, James Alaro, John J. Welch, Belmira Rodrigues, Verna Vanderpuye, Joe B. Harford, Makeda Williams
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
PURPOSE: The burden of cancer in Africa is growing rapidly, and increased cancer research on the continent is a critical component of an effective response. In 2010, the US National Cancer Institute, in partnership with the African Organization for R
Externí odkaz:
https://doaj.org/article/a46f108d5de0435eb65940851213ceaa
Publikováno v:
Viruses, Vol 14, Iss 4, p 739 (2022)
SGT-53 is a novel investigational agent that comprises an immunoliposome carrying a plasmid vector driving expression of the human TP53 gene that encodes wild-type human p53. SGT-53 is currently in phase II human trials for advanced pancreatic cancer
Externí odkaz:
https://doaj.org/article/26b801d1165c4d7d9935b5d4b34184e7
Publikováno v:
OncoImmunology, Vol 7, Iss 10 (2018)
The tumor suppressor p53 responds to genotoxic and oncogenic stresses by inducing cell cycle arrest and apoptosis. Recent studies suggest that p53 also participates in the regulation of cellular immune responses. Here, we have investigated the potent
Externí odkaz:
https://doaj.org/article/bb4300d60ed1479ba1938f754e3a5d91
Autor:
Ellen C. Moore, Lillian Sun, Paul E. Clavijo, Jay Friedman, Joe B. Harford, Anthony D. Saleh, Carter Van Waes, Esther H. Chang, Clint T. Allen
Publikováno v:
OncoImmunology, Vol 7, Iss 7 (2018)
Loss or mutation of TP53 has been linked to alterations in anti-tumor immunity as well as dysregulation of cell cycle and apoptosis. We explored immunologic effects and mechanisms following restoration of wild-type human TP53 cDNA in murine oral canc
Externí odkaz:
https://doaj.org/article/0597348176a347c2bbfba1afd61182b4
Autor:
Kelly A. Hirko, Amr S. Soliman, Ahmed Hablas, Ibrahim A. Seifeldin, Mohamed Ramadan, Mousumi Banerjee, Joe B. Harford, Robert M. Chamberlain, Sofia D. Merajver
Publikováno v:
Journal of Cancer Epidemiology, Vol 2013 (2013)
Background. This study was undertaken to evaluate trends in breast cancer incidence in Egypt from 1999 to 2008 and to make projections for breast cancer occurrence for the years 2009–2015. Patients and Methods. We utilized joinpoint regression and
Externí odkaz:
https://doaj.org/article/180e07bd06054fdea26ca3bfe19c297b
Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
Autor:
Sang-Soo Kim, Caroline Doherty, Manish Moghe, Antonina Rait, Kathleen F. Pirollo, Joe B. Harford, Esther H. Chang
Publikováno v:
Cancers; Volume 14; Issue 20; Pages: 5092
Because lung cancer remains the most common and lethal of cancers, novel therapeutic approaches are urgently needed. RB94 is a truncated form of retinoblastoma tumor suppressor protein with elevated anti-tumor efficacy. Our investigational nanomedici
Autor:
J. Welch, Kalina Duncan, Amanda L. Vogel, Jordan A Freeman, Belmira Rodrigues, Verna Vanderpuye, Joe B. Harford, Makeda J. Williams, James Alaro
Publikováno v:
Journal of Global Oncology
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
Journal of Global Oncology, Vol 5, Pp 1-8 (2019)
PURPOSE The burden of cancer in Africa is growing rapidly, and increased cancer research on the continent is a critical component of an effective response. In 2010, the US National Cancer Institute, in partnership with the African Organization for Re